(Total Views: 295)
Posted On: 03/14/2018 6:24:55 AM
Post# of 72446
For IPIX it depends on the first deal. If they get a decent up front payment of at least $30 mil with milestones for brilacidin we'll be in good shape. I'm thinking at first we'll pass $5 and get our up-listing. If we see this, and they do get up listed we're on the map.
Most bio's I've followed have gone from where we are now to $5 - $14 on the first real deal and then fluctuate like crazy through phase 3. CBAY, ACAD, CRBP, CNAT and some others. I think if big pharma believes what we've been led to believe about the science our potential surpasses all of them. Right now it's about getting the prurisol data, if it's marketable, like I think it will be, then our pipeline is solid and it'll just be a matter of months - maybe even weeks before at least one of the CDA's is revealed and we get that first deal.
Measuring risk/reward till then isn't easy. Leo is doing great keeping things quiet until there is really something to put out. IPIX is one of my largest holdings, and I sleep well at night.
Most bio's I've followed have gone from where we are now to $5 - $14 on the first real deal and then fluctuate like crazy through phase 3. CBAY, ACAD, CRBP, CNAT and some others. I think if big pharma believes what we've been led to believe about the science our potential surpasses all of them. Right now it's about getting the prurisol data, if it's marketable, like I think it will be, then our pipeline is solid and it'll just be a matter of months - maybe even weeks before at least one of the CDA's is revealed and we get that first deal.
Measuring risk/reward till then isn't easy. Leo is doing great keeping things quiet until there is really something to put out. IPIX is one of my largest holdings, and I sleep well at night.
(4)
(0)
